• Explore /
  • Poster
  • / Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).

Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).

Abstract Poster

Authors

Arjun Balar

Arjun Vasant Balar

Perlmutter Cancer Center, NYU Langone Health, New York, NY

Arjun Vasant Balar , Robert Dreicer , Yohann Loriot , Jose Luis Perez-Gracia , Jean H. Hoffman-Censits , Daniel Peter Petrylak , Michiel Simon Van Der Heijden , Xiaodong Shen , Beiying Ding , Teresa Ramirez-Montagut , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02951767 and NCT02108652

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 394)

DOI

10.1200/JCO.2019.37.7_suppl.394

Abstract #

394

Poster Bd #

G7

Abstract Disclosures

Similar Posters

First Author: Alejo Rodriguez Vida

Poster

2022 ASCO Genitourinary Cancers Symposium

Impact of FDA label change on immunotherapy for metastatic urothelial cancer (mUC) and subsequent changes in mortality.

Impact of FDA label change on immunotherapy for metastatic urothelial cancer (mUC) and subsequent changes in mortality.

First Author: Daniel Vader

First Author: Jonathan E. Rosenberg

First Author: Nabil Adra